- Home
- PHAR vs AIO Comparison
PHAR vs AIO Comparison
Compare PHAR & AIO Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- PHAR
- AIO
- Stock Information
- Founded
- PHAR 1988
- AIO 2019
- Country
- PHAR Netherlands
- AIO United States
- Employees
- PHAR N/A
- AIO N/A
- Industry
- PHAR Biotechnology: Pharmaceutical Preparations
- AIO Finance/Investors Services
- Sector
- PHAR Health Care
- AIO Finance
- Exchange
- PHAR Nasdaq
- AIO Nasdaq
- Market Cap
- PHAR 798.2M
- AIO 808.3M
- IPO Year
- PHAR N/A
- AIO N/A
- Fundamental
- Price
- PHAR $13.70
- AIO $24.19
- Analyst Decision
- PHAR Strong Buy
- AIO
- Analyst Count
- PHAR 3
- AIO 0
- Target Price
- PHAR $30.00
- AIO N/A
- AVG Volume (30 Days)
- PHAR 12.8K
- AIO 141.5K
- Earning Date
- PHAR 07-31-2025
- AIO 01-01-0001
- Dividend Yield
- PHAR N/A
- AIO 9.05%
- EPS Growth
- PHAR N/A
- AIO N/A
- EPS
- PHAR N/A
- AIO N/A
- Revenue
- PHAR $339,836,000.00
- AIO N/A
- Revenue This Year
- PHAR $12.88
- AIO N/A
- Revenue Next Year
- PHAR $8.54
- AIO N/A
- P/E Ratio
- PHAR N/A
- AIO N/A
- Revenue Growth
- PHAR 22.44
- AIO N/A
- 52 Week Low
- PHAR $6.73
- AIO $15.09
- 52 Week High
- PHAR $17.08
- AIO $20.25
- Technical
- Relative Strength Index (RSI)
- PHAR 67.43
- AIO 45.62
- Support Level
- PHAR $12.13
- AIO $23.52
- Resistance Level
- PHAR $12.76
- AIO $24.54
- Average True Range (ATR)
- PHAR 0.89
- AIO 0.34
- MACD
- PHAR 0.13
- AIO -0.09
- Stochastic Oscillator
- PHAR 44.41
- AIO 45.27
About PHAR Pharming Group N.V.
Pharming Group is a biopharmaceutical company focused in transforming the lives of patients with rare, debilitating, and life-threatening diseases. The company is actively developing and commercializing a diverse portfolio of innovative treatments, including both biologics and small molecule therapies. Its commercial products are RUCONEST, approved for the treatment of acute attacks in adult and adolescent patients with hereditary angioedema, or HAE; and Joenja (leniolisib), a small-molecule kinase inhibitor, developed for the treatment of activated phosphoinositide 3-kinase delta syndrome.
About AIO Virtus Artificial Intelligence & Technology Opportunities Fund of Beneficial Interest
Virtus Artificial Intelligence & Technology Opportunities Fund is a diversified, limited-term, closed-end management investment company. The fund's investment objective is to provide total return through a combination of current income, current gains, and long-term capital appreciation.